USFDA warns Sun Pharma for Dadra unit violations, stock falls 2%

Sun Pharmaceutical Industries has received a warning letter from US Food and Drug Administration (USFDA) over violations at its Dadra facility, the company said on Wednesday. It added that the letter summarised the violations with respect to Current Good Manufacturing Practice (CGMP). Shares of the company fell around 2% after its opening on Thursday to trade at ₹1,479.